Strandberg , T E 2022 , ' Benefits and limitations of statin use in primary cardiovascular prevention : recent advances ' , Polskie Archiwum Medycyny Wewnetrznej , vol. 132 , no. 5 , 16258 . https://doi.org/10.20452/pamw.16258
Title: | Benefits and limitations of statin use in primary cardiovascular prevention : recent advances |
Author: | Strandberg, Timo E. |
Contributor organization: | HUS Internal Medicine and Rehabilitation Timo Strandberg / Principal Investigator Department of Medicine Clinicum University of Helsinki |
Date: | 2022-05-30 |
Language: | eng |
Number of pages: | 8 |
Belongs to series: | Polskie Archiwum Medycyny Wewnetrznej |
ISSN: | 0032-3772 |
DOI: | https://doi.org/10.20452/pamw.16258 |
URI: | http://hdl.handle.net/10138/346352 |
Abstract: | The status of low-density lipoprotein (LDL) cholesterol is strong as an essential cause of atherosclerotic vascular disease (ASCVD) and primary target of lipid lowering. Drugs affecting primarily LDL cholesterol through an increase of LDL receptor expression are the backbone of current therapy, and generic statins are generally safe, effective, and inexpensive drugs serving this purpose. Statins are indicated for practically all patients in secondary prevention, whereas treatment in primary prevention (healthy individuals) is based on a calculated 10-year risk of ASCVD. At ???borderline??? (from 5% to |
Subject: |
cardiovascular disease
elderly primary prevention statin LDL CHOLESTEROL OLDER PATIENTS DISEASE RISK PLACEBO TRIAL INDIVIDUALS MORTALITY THERAPY EVENTS 3121 General medicine, internal medicine and other clinical medicine |
Peer reviewed: | Yes |
Rights: | cc_by_nc_sa |
Usage restriction: | openAccess |
Self-archived version: | publishedVersion |
Total number of downloads: Loading...
Files | Size | Format | View |
---|---|---|---|
inv_Strandberg_rev.pdf | 286.4Kb |
View/ |